04:44 PM EDT, 10/24/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday its KRAS G12D degrader candidate, ARV-806, demonstrated robust and durable tumor inhibition and potent target degradation in preclinical models of pancreatic, colorectal, and lung cancers.

The company said ARV-806 achieved picomolar potency in degrading KRAS G12D and showed more than 25-fold stronger antiproliferative activity than other G12D-targeting therapies in development.

A single intravenous dose in a colorectal tumor model degraded over 90% of KRAS G12D for seven days, with reduced cancer cell proliferation and increased expression of the pro-apoptotic protein BIM.

The findings were presented at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston.

ARV-806 is being evaluated in a phase 1 trial in patients with KRAS G12D-mutated solid tumors, according to the company.

Shares of Arvinas ( ARVN ) were down 1.7% in after-hours activity.